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CHAPTER 1. CONFORMATIONALLY RESTRICfED PEPTIDE MIMICS AND 
IDV PROTEASE INlllBffiON. 
1.1. Introduction. 
Molecular recognition plays a vital role in a wide variety of biochemical 
transformations. Of particular interest to chemists, biochemists, and biologists is 
the process by which enzymes recognize and bind substrates in the catalytic process. 
The relationship of peptide structure to properties and biological activity is the most 
important aspect of studies of molecular recognition. Enzyme binding studies are 
complicated because of the numerous variables in the binding process, which 
include the flexibility of substrates and inhibitors in solution, the paucity of enzyme 
structural information, and the dynamic nature of the enzyme/substrate complex 
structure. 
Recent advances in X-ray crystallography and molecular modeling have 
allowed researchers to determine the coordinates of many bound inhibitor/enzyme 
complexes and analyze the bound conformation of inhibitors. The mv -1 protease 
has been the subject of several recent X-ray crystallographic studies, so the general 
topography of bound mv -1 protease inhibitors is well established. In addition, 
numerous HIV protease inhibitor and substrate binding studies have established the 
enzyme's ligand preferences at important binding subsites. 
Conformationally restricted pseudopeptide substrates and inhibitors have an 
entropic binding advantage over their more flexible, unconstrained analogues and 
have been found to enhance binding in several studies. Rationally designed, 
conformationally restricted peptide mimics that ftx backbone and side chain 
2 
orientation in the "bound" geometry enhance binding and can be used to probe the 
enzyme binding site by varying the properties of the restricted ligands. 1 ,2,3-
Trisubstituted cyclopropanes are among the most effective conformationally 
restricted dipeptide mimics. They ftx both the amino acid side chain and backbone 
orientations and can be efficiently synthesized via enantioselective transition metal 
catalyzed intramolecular cyclization of allyl diazoacetates. 
Our goal in this research project was to design a series of substituted 
cyclopropanes as peptide mimics, develop enantioselective synthetic pathways to 
these compounds, and investigate methods of coupling di- and mono-peptide 
mimics into effective HIV protease inhibitors that can be used to evaluate the effect 
of phi ( cj)) and chi (X) angle restrictions on inhibitor binding . 
1.2. Conformational restriction and entropic binding advantage. 
Small peptides are quite flexible in solution. Conformational 
interconversions not requiring peptide bond rotations may occur at milli-second or 
faster time scales, and peptide bond rotations occur on the time scale of seconds. I 
Upon binding to an enzyme active site, the section of the substrate peptide that is 
bound to the host enzyme has a relatively rigid three-dimensional (3-D) structure. 
Conformational restrictions that mimic the bound 3-D structure of a peptide offer an 
entropic binding advantage per the four principles of conformational restriction in 
binding that are set forth below. 
( 1) Binding involves loss of entropy for the ligand, the enzyme and the 
system 
{2) Binding energies pay for entropic advantage 
3 
(3) You must pay for loss of entropy only once 
(4) Entropy loss "bought" in synthesis gives binding advantage 
In considering the advantages of conformational constraint, it is important to 
realize that the concept of conformational constraint is a double-edged sword in that 
restrictions which do not closely mimic the bound 3-D structure of the peptide of 
interest can negatively affect the binding process. Although some variations from 
optimal geometry may be compensated for by an induced fit between the peptide 
mimic and the enzyme, significant deviation may prevent binding or reduce binding 
efficiency. 
1.2.1. Natural amino acids and conformational restraint 
Peptide conformation and topography are described by phi (c(»), and psi ('IJ), 
and chi (X) angles as illustrated in Figure 1. Phi ( ct») represents the amount of 
rotation at the bond between an amino acid residue's nitrogen and a-carbon and psi 
('!') represents the amount of rotation at the bond between the a-carbon and 
carbonyl carbon atoms. Together, ct» and X angles for each residue in the peptide 
chain completely defme main chain conformation since amide bonds are considered 
to be rigid and planar. In a fully extended polypeptide chain 'I'= ct» = 1800 and in 
the sterically favored extended Ji-sheet backbone configuration residue angles of 'II 
= +1350 and c(» = -1350 are common. Chi 1 (Xl) represents the amount of rotation at 
the bond between the a-carbon and Ji-carbon of a residue and defmes the 
orientation of the residue's sidechain. Three common examples of x• orientations 
for Ji-substituted amino acids are shown in Figure 1. Gauche(+) (XI= 600), gauche 
(-) (X1 = -600) and anti (Xl = 180°) are commonly used in discussion of side chain 
4 
orientations and their abbreviations of g+, g·, and anti will be used in the 
discussion below.2 
0 
~~ ~ NH x• 
R 
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Figure I 
Proline (Pro), valine (Val) and isoleucine (De) all have structural features 
that affect the confonnation of peptides into which they are incorporated. Proline's 
cyclic structure restricts q, and x angles causing it to have a profound influence on 
the confonnations of peptide segments and protein folding. 3 Proline is strongly 
favoured in position i+l of (i-tums and is of interest in this study because it 
occupies the PI' site in three of the eight substrates for the mv -1 protease discussed 
below.l 
Val and De are both Ji-substituted by a methyl group, which in conjunction 
with their other (i-ethyl or methyl substituents, imparts a preferential X angle to the 
residue. Figure 2 details the low-energy side chain confonnation for Val and De 
about the Ca-CJi bond. Sterle considerations indicate that the confonnation B 
would be preferred. This preference should impart enough local confonnational 
stability to affect molecular recognition. Both these (i-substituted amino acids are 
5 
important residues in the HIV inhibitors used as geometrical templates in this study 
and their "bound" conformations will be analyzed in detail below. 
H CH3 R CJ¥ c~ CO*H 
/ " R N CH3 H N R H~ N H 




1.2.2. Conformational constraint in peptide mimics. 
Two levels of conformational constraint have been utilized to design peptide 
and protein ligands with specific physical, chemical, and biological properties. 
Global restraints in the form of ~tum and a-helix templates impart specific 
secondary backbone structures to peptides.4 Local conformal restraints bias or 
constrain side chain moieties of a peptide or pseudopeptide residue to a particular 
side chain conformation x-angle without affecting the overall backbone 
configuration. Seven general methods of inducing local constraint have been 
reviewed by Hruby and are listed below with the expected effects on conformation. 5 
General Methods of Inducin& Local Constraints in Pwtides 
Method 
(1) Backbone N- alkylation 
(2) Backbone C -alkylation 
(3) 0-amino acid or Proline Substitution 
(4) Bulky Side Chain Groups 
(5) Amide Bond Surrogates 
trans (double bond) 
cis ( tetrazole) 
( 6) Cyclic Amino Acids 
side chain to backbone 









Backbone N- and Ca-alkylation and the addition of bulky side chain groups 
induce local constraints on peptide conformation by limiting the number of 
sterically favorable conformations about the Ca to N and Ca to carbonyl carbon 
bonds. N-alkylation favors cis configurations at the affected amide bond and Ca-
alkylation tends to initiate turns in peptide backbone chain orientation. The 
extended Ji-sheet (or Ji-strand) configuration in a peptide generally represents the 
most stericly favored conformation with all trans orientation at amide bonds and no 
turns. Backbone N- and Ca-alkylation, and amide bond surrogates disrupt the 
extended Ji-sheet conformation needed to mimic the geometry observed in bound 
inhibitors of the HIV protease and bulky side chain groups are not be expected to fit 
in the enzyme's relatively specific and compact binding sites, so N-alkylation, C-
alkylation, amide bond surrogates, and bulky side groups were not considered as 
7 
potential methods of restricting conformation when designing potentia! constraints 
to probe the HIV protease. Proline or proline analogue substitution, cyclic amino 
acids and pseudo-peptides and !}-substituted amino acids were considered as 
potential constraints and are reviewed below. 
1.2.3. Proline and proline analogues as conformational constraints. 
Schreiber asserts that theN-acyl substituted pyridine 1 serves as a "twisted" 
proline mimic in substrate specificity studies for the human rotamase FKBP. This 
"proline analogue" was used to orient adjacent ligands in rapamycin and a synthetic 
analogue FK506 into the S 1 binding site of the enzyme. Molecular modeling 
studies of the pyridine based inhibitors indicated that the enzyme binding site would 
accommodate branched hydrophobic residues better than other types of residues and 
this was found to be the case in the related substrate specificity study. 6 The 
residues studied were adjacent to, and not directly constrained by, the mimic and the 
cyclic mimic is still relatively flexible. It is difficult to attribute a preferred 
orientation to the molecule with enough confidence to predict the twisted geometry 
Shreiber asserts as a major factor in binding and more recent work involving bound 
FK506/X-ray crystal structures has shown this hypothesis to be incorrect. The 
peptidyl-prolyl amide bond was bound in a planar configuration.? 
8 
1 
Hydroxyalkyl isosteres like 2, which mimic proline at the Pl' subsite of 
potential protease inhibitors, have been synthesized stereoselectively.8 These 
compounds are designed to mimic both the sp3 geometry of transition state scissile 
carbonyl carbon and the backbone orientation of the Xxx-Pro scissile amide bond of 
compounds like 3 below. 
R ~ nH AA· N AA;, ,, NH NH\ ·,,H -----+ HO-' H 
0 0 A A i+ 3 0 A A i+ 3 
3 2 
Substrate-based, reduced amide inhibitors similar to compound 4 have been 
used to develop effective inhibitors of renin.9 The tetrahedral geometry of the 
reduced carbon mimics the accepted transition state geometry at the carbonyl 
carbon. The proline nitrogen mimics the basic nitrogen of the amide cleavage 
9 
product, and the proline ring provides conformational restraint. Reduced amide 
proline mimics have been incorporated into the Pl' site of HIV-1 protease inhibitors 
with some success but the best inhibitors (Inhibition constants (Ki) = 19 J,LM) are not 
as effective at the inhibitor PI' position as other Pl-Pl' transition state mimics 






Kemp and Carter constructed bicyclic J3-enaminonitrile 5 as y-turn templates 
and conformationally restricted analogues of polypeptides from L-hydroxyproline . 
The bicyclic structures were not only more rigid than monocyclic J3-enaminonitriles, 
which are also potential conformational restraints, but they are more resistant to 
epimerization because the bridgehead carbon cannot readily achieve the sp2 
geometry necessary for epimerization per Bredt's rule. II Although conformational 
analysis indicates that these mimics may be useful as conformational restraints, 
there are no studies of their effectiveness in pseudopeptides. 
Proline and the proline mimics discussed above initiate turns and position 
side chains of adjacent residues indirectly. They do not, however, readily 
accommodate an extended J3-sheet configuration and, there are no examples, to date, 
where substituted prolines or psuedo-prolines were used to directly position 
substituents in a binding site. 
10 
1.2.4. (3-alkylated amino acids as conformational restraints. 
Enantiomers of (3-methylated D-and L-phenylalanine and tyrosine were used 
to modify systematically the topography of enkephalin analogue [D-Pen2,D-Pen5] 
enkephalin (DPDPE) (6), which is an effective o opioid receptor selective 
agonist.l2 By methylating at the pro-S position (R2) or the pro-R position (R1), 
sidechain x 1 angle preferences could be controlled by limiting the number of 
sterically preferred conformations about the Ca to C~ bond. NMR studies of the 
conformation of resulting compounds indicated that the backbone conformation of 
this compound was not changed by the modification. However, the (3-alkylated 
aromatic side chains did show a defmite conformational preference (g- for R2 = Me 
and g+ for R 1 = Me) that defmed a new topography for the pseudopeptide and 







Hruby carried the (3-alkylation concept one step further, and incorporated (3-
methyl substituted Phe and Tyr amino acids into somatostatin analogues. He 
discovered that (3-alkylation improved or diminished the potency of the analogues 
11 
compared to somatostatin depending on whether the pro-S or pro -R position of the 
amino acids was methylated.l4 No obvious trends that would allow prediction of 
binding effectiveness were discovered or exploited in this study, but the ability of 
conformational restraints to effect both topography and binding was well 
established. 
1.2.5. Cyclic amino acid and dipeptide mimics as conformational restraints. 
1.2.5.1. Lactam bridged dipeptide mimics. 
Some of the most effective recent work in cyclic conformational constraint 
involves lactam bridged dipeptide mimics. These mimics, unlike proline, link two 
residues so they are capable of directly affecting the orientation of both side chains 
in the dipeptide, thereby offering rigidity to the backbone without loss of an 
interaction site. 
Freidinger was one of the frrst researchers to investigate lactams as 
conformational restraints in peptides. He designed and devised synthetic procedures 
for lactam bridged dipeptides of the type in Figure 3.15 He incorporated one of 
these dipeptides (N = 1) into an analogue of luteinizing hormone-releasing hormone 
(LH-RH). The conformationally constrained analogue was 8.9 times more potent 
in vitro than LH-RH and was also more potent in vivo. Freidinger attributed 
increased potency to improved receptor binding as a result of the pseudodipeptides' 
conformational restriction, and be proposed that these cyclic molecules initiated a ~ 
tum which was complimentary to receptor binding sites.16 
12 
Figure 3 
y - Lactam bridged dipeptide isosteres based on compound 7 were modeled 
and suggested recently as possible restrictions at the P2-P3 site of human renin in 
1988. They were successfully incorporated into the P3-P2 site of a renin inhibitor 
that included a hydroxyethylene transition state analogue at the Pl-P2 position. The 
restricted inhibitor was four fold more potent than the corresponding acyclic 
analogue, inhibiting human plasma renin with an IC50 value of 6.5 nM as opposed 
to 26 nM for the acyclic case. The same P2-P3 site dipeptide mimic, however, 
actually reduced binding by two orders of magnitude over the acyclic analogue in 
another inhibitor that included a statine transition state analogue at the Pl-P2 
position (IC50 at lQ-5 M compared to lQ-7 M).l7 
7 
A series of renin inhibitors with lactam-bridged Pl-Pl' dipeptide mimics 
based on the statine analogue 4(s)-amino-5-cyclohexyl-3(s)-hydroxypentanoic acid 
(ACHP A) 8 were designed and studied by Williams at Merck. Effectiveness of 
13 
inhibition was found to depend on: (1) ring size [IC50 (N = 1) < IC50 (N = 2) < 
IC50 (N = 3)]; (2) substitution at R1, R2 and R3 (tolerating moderately sized 
groups such as -CH3, -CH=CH2, and -CH2CH3 at all positions without much 
degradation in activity); and (3) stereochemistry at C2 and C3 (S,S decidedly 
preferred to R,S or S,R). The best lactam bridged inhibitors exhibited Ki values on 
par with their non-constrained analogues with an IC50 of 1.3 nM against human 
renin for the best cyclic case and 1.5 nM for the best non-constrained analogue, but 
it should be noted that none were better renin inhibitors. IS 
Laszlo investigated 3-amino-4-phenyl-2-pipiridinones 9 and 4-amino-2-
benzazepin-3-ones 10 as conformationally restricted phenylalanine isosteres at the 
P2-P3 site on renin. Good inhibition was achieved (IC50 = 21 nM for best cyclic 
inhibitor), but the best cyclic mimic was 25 times less potent than its acyclic 
analogue. The size of the R group at the N-terminus was found to be important for 
bioactivity with N-acetyl derivatives being more potent than N-BOC. Molecular 
modeling studies indicated that the larger N-terminal group would interfere 
sterically with the binding process, and the results of the binding studies support 
that conclusion.I9 
(\\ ··~·13 1 "' AA ;+2 
10 
14 
The overriding theme in the above lactam-bridged cases is one of parity with 
non-constrained analogues in inhibition studies and promise as probe templates for 
site mapping and binding studies. If a conformationally restricted mimic like the 
above 13-Iactam can be established as an effective inhibitor, then the 
conformationally restricted side chain's size and properties can be varied to probe or 
map the steric and electronic features of the enzyme subsite pocket. The ability of 
researchers to modify activity by introducing a lactam-bridged conformational 
constraint has been well established by these recent studies. 
1.2.5.2 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) as a constrained 
phenylalanine mimic. 
.e 
D-Tic 11 was designed by Hruby to constrain both x1 and x2 of the Phe 
moiety of a J.l opioid receptor to a g· conformation in the development of the most 
J.l vs p selective compound known to date (9000 fold selective). Scheme 1 sets forth 
the two possible conformations for the side chain of D-Tic. 
15 
SCHEME 1 
~H H .~ 
-< H 0 
g+ 
Analysis of NMR coupling constants between the Ca and cp hydrogens of a 
CfP receptor antagonist with D-Tic incorporated in place of Phe revealed that the 
D-Tic aryl side chain exists exclusively in the g" confonnation.20 
In an interesting development, the D-Tic residue was found to prefer the g+ 
confonnation when it was inserted into an interchain position instead of the N-
tenninal positions studied above. 21 a,J}-Dimethylation of the pipecolic acid ring 
was found to stabilize the g" confonnation for N-acylated a,(3-dimethylated Tic 
derivatives per the example of (3R,4R)-D-Tic (12) so that both g- and g+ 





NHI JNH~CO H 0 2 
14 
- ---- ---------------------------------------------------------------------~ 
16 
1.2.5.3 Other cyclic constraints. 
Kahn inserted bicyclic heterocycle 13 into a moderately active HIV 
protease inhibitor at the P2-P3 sites and achieved 26 nM inhibition in vitro.23 He 
has proposed this fi-tum dipeptide mimic as a foundation for examination of 
protease secondary structure specificity. As will be discussed later in detail, the size 
of this bicyclic compound probably would limit its effectiveness as a probe template 
to the poorly defmed S3 and S3' subsites in the HIV protease. 
Hayashi has developed a cyclic imino acid moiety 14 that incorporates a 
ureido group as the C-terminal group for effective ACE inhibitors. The ureido 
carbonyl group provides enhanced hydrogen bonding to the enzyme because the 
urethane function polarizes the C-0 bond more effectively than a normal amide 
causing a higher charge density at the oxygen and the five membered ring provides 
conformational restraint. 24 
1.2.5.4. Cyclopropanes as conformational restraints. 
Early interest in cyclopropanes as a conformational restraints in biological 
systems centered around studies of pyrethyroid insecticides which incorporate 
crysanthamic acid 15. The importance of this cyclopropane moiety in molecular 
recognition in these compounds is demonstrated by the improved potency and 
selectivity of insecticides containing optically active lR-trans-crysanthamic acid 
and IR-cis-permethric acid 16 over racemic compounds. The lR-trans enantiomer 
apparently orients the methyl groups and the pseudo peptide backbone in a 
biologically active configuration that is not prefered by the IS-trans configuration 
or acyclic analogues. 25 
17 
R~C02H 
• Xts •. ,., 
16 R = C 1 
A group of Czechoslovakian researchers attempted to replace proline in 
oxitocin analogues with 1-aminocyclopropane-1-carboxylic acid 17 (Ace) to 
enhance uterotonic activity over that of oxitocin. Substitution of Ace for proline in 
these analogues lowered biological activity. Since the conformational restriction 
imposed by 17 does not mimic common backbone configurations for turns or 
sheets, this result should have come as no surprise.26 Ace (17) has also been 
incorporated in enkephalin analogues, oxytocin analogues, aspartyl dipeptides, 
carboxypeptidase A inhibitors and tetra Ace ~sheet templates with some success. 
Enkephalin analogues with Ace replacing a Gly residue and oxytocin analogues 
have either enhanced or caused no change in potency. The best carboxypeptidase A 
inhibitors exhibited a Ki of 8x I0-4 M with inhibition occurring about 2.3 times 
faster than hydroysis of the substrate, but no comparisons were made to linear 
analogues. Cyclopropyl amino acid 18 was used to mimic Phe in position 4 of 
enkephalin where it enhanced opioid receptor selectivity. Aspartyl dipeptides 
containing Ace were sweet tasting and compound 18 was also incorporated in 
analogues of aspartate in an unsuccessful attempt to map "sweetness receptors".27 
Melnick and co-workers at Upjohn proposed dimethylcyclopropane valine 
mimics at PI and Pl' sites on protease dipeptide transition state mimics 19 and 20. 




Ohfune developed L-a-(carboxycyclopropyl) glycines as conformationally 
restricted analogues of L-Glu. He synthesized four diastereomers and conducted in 
vivo tests of neurotransmitter action in isolated rat spinal cord. The (2S, 3R, 4S)-
isomer activated the N-methyl-D-aspartic acid (NMDA) subtype receptor more than 
established agonists did. 29 
1,2,3-Trisubstituted cyclopropanes 21 and 22 were incorporated as 
combined N-terminal and P3 replacements in a series of renin inhibitors and tested 
for inhibitory potency in what is, to date, the most complete and elegant study of 
cyclopropanes as conformational constraints. Compounds 21 and 22 were designed 
to mimic extended ~sheet backbone conformation and flx the xi angle of the aryl 
residue. Inhibitor 23 rivaled the most potent flexible inhibitor 24 in activity, and 
indications are that the conformationally constrained P3 replacement 23 mimics the 
topography at P3 of the bioactive conformation of its flexible analogue and the L-
--------------------
19 
phenylanaline at the P3 site of the substrate. By modifying stereochemistry and 
substitution around the cyclopropane ring in a series of 10 inhibitors, potency could 
be varied by a factor of 10. Furthennore, L-amino acid mimics were generally 
better than D-amino acid mimics, and L-Phe substituted mimics were better than 
their benzyl analogues.30 Although the constrained inhibitors "tied" the flexible 
inhibitors in potency in this study, it is evident that substituted cyclopropanes can 
serve as templates from which to map the renin S3 subsite. 
~ ~ 
0 ~NS ~NS 0 OH 0) 0 H oY.~\. ~··h ~·«·· ~··~ 
.. . O o• 0 • r. N o• 
23 24~ 
1.2.6. Conclusion of Confonnational Restraint Review. 
Substituted cyclopropanes were selected as confonnational restraints in this 
study because they ftx both cp (extended fl-sheet or bend) and x (If or,g+, or anti) at 
angles desired in lflV protease inhibitors without sacrificing the interaction of a 
residue at a crucial subsite. They have established efficacy in renin and are 
available through relatively convenient enantioselective pathways. Potential 
drawbacks of this selection include the loss of an amide N-H (replaced by C2 of the 
mimic) for hydrogen bonding. This was compensated for in our mimic design by 
proposing a benzyl amide end group to replace the carboxy benzyl of an effective 
inhibitor. 
20 
Confor.national restrictions, in general, have proven useful in peptide 
chemistry particularly in opioid receptor and LH-LR studies. but their performance 
to date in protease inhibition studies has been parallel to acyclic analogues in all but 
the one case discussed in Section 1.2.5. I. Perhaps the topology required of an 
aspartic protease is more restrictive than for the opioid receptors. and researchers 
need to more exactly match the bioactive conformation to achieve advantages in 
potency. 
1.3. Human Immunodeficiency Virus Protease. 
Human immunodeficiency virus (IDV) is the cause of acquired immune 
deficiency syndrome (AIDS). HIV -1 is a retrovirus in the Retroviridae family and 
belongs to the sub-family lentivirinae [leoti is Latin for slow referring to the long 
incubation period] along with the viridae that cause encephalopathies, pneumonitis, 
arthritus. and hemolytic anemia. HIV contains a small RNA genome which is 
translated into DNA in the host cell by reverse transcriptase. a DNA polymerase 
brought to the host by the viral particle. Another essential enzyme. integrase, then 
aids in inserting the HIV DNA genome into the host DNA. The host cell then 
produces large polyprotein precursors for core (gag), enveiope (env), and 
polymerase (pol) proteins. These precursors are processed by the HIV protease to 
yield the structural proteins and enzymes of the mature viron. 31 The protease is 
essential for viral replication and is a popular therapeutic target in current drug 
research. 32 It also serves as an excellent platform for molecular recognition studies 
21 
because of its relative simplicity and the large amount of information available on 
its structure. 
1.3.1. HN -1 protease structure. 
Recombinant DNA techniques and total chemical synthesis have been used 
to produce HIV -1 protease because isolation of tl.e natural protease is dangerous 
and yields only minute quantities of material. 33 
From X-ray crystal structures and other work, the HN protease has been 
determined to be a 99 amino acid aspartic protease with a molecular weight of 27 
KD. In its native active form, it is a homodimer with "flaps" over an Asp-Thr-Gly 
active site.34 Figure 4a shows an X-ray crystal structure of the protease dimer with 
one monomer colored red and the other colored blue. A bound inhibitor (green) is 
included to highlight the flaps over the active site. Figure 4b shows a cut-away 
view of the one monomer with bound inhibitor. The residues involved in the dimer 
junction are colored purple. The enzyme has a rough C2 symmetry, and subsites S2 
through S2' are well defmed. S3 and S3' sub-sites are less conspicuous and are 





1.3.2. HIV -1 protease function. 
One proposed mechanism for aspartic protease cleavage mechanism 
involves the two Asp residues at the active site and a water molecule as set forth in 
Scheme 2.35 The transition state between the "just bound" conditions described in 
situation A of Scheme 2, and intermediate state B, in which the carbonyl carbon has 
been transformed to a diol, is suspected to be tetrahedral in nature. This 
mechanism is based on the concept that the transition state geometry about the 
scissile bond is bound more tightly than the substrates natural amide bond geometry 
thereby lowering the activation energy of the cleavage reaction. The tetrahedral 
nature of the transition state is an important feature of this proposal and is exploited 
in a variety of transition state inhibitors. 
H 






Substrate specificity of the HIV protease is very broad, and substrate 
sequences have been classified into three groups depending on residues present at 
PI' and P2' in Table 1.36 Some trends can be observed: (1) Phe and Tyr are 
24 
common at P1; (2) Pro, which is not normally accommodated in the P1' position of 
other proteases such as trypsin, is found in three of the eight sequences at PI'; (3) 
there is a general trend toward hydrophobic residues at P2' and P3'; and (4) P2 and 
P2' both accept lie, a branched non-polar residue. 37 
Table 1 
~~ ~uoo~ 
P3 P2 P1 ~ PI' P2' P3' 
~-NHlCONHlCONHlCONHlCONHlCONHlCO-~ 
R1 R2 R3 R1 R2' R3' 
f~~~-~~ 
~ S3 S2 S1 • SI' S2' S3' ~ 
I 
ENZ'YME ACTIVE SITE 
Classification of HIV -1 Protease Substrates 
Class A 
P3 P2 P1 P1' P2' P3' 
Gln Asn Tyr Pro lle Val 
Phe Asn Phe Pro Gin lle 
Leu Asn Phe Pro lle Ser 
Class B 
Thr lle Met Met Gln Arg 
Gly Asn Phe Leu Gin Ser 
Gin Ala Asn Phe Leu Gly 
Lys lle Leu Phe Leu Asp 
Class C 
Arg Val Leu Ala Glu Ala 
In a more recent analysis of HIV proteinase subsite preferences researchers 
found that: ( 1) subsites S 1 and S 1' showed explicit preference for hydrophobic 
residues; {2) (3 branched amino acids and Pro were not tolerated at S1; and {3) S2 
showed a preference for small polar and apolar residues. All amino acids could be 
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accommodated at S3, which is consistent with graphical analysis of subsite size and 
composition based on X-ray data and other residue substitution studies that indicate 
that the P2 through P2' residues are critical in binding to the enzyme. 38 
One interesting study by Tommasselli showed that HIV protease degraded 
actin, troponin, and Alzeheimer amyloid precursor protein (AAP). Although it was 
proposed that the protease could possibly damage regulatory and structural cellular 
proteins, there was no mention of studying the effect of AIDS on victims of 
Alzheimer's disease. 39 
1.3.3. HIV protease inhibitors: Transition State Mimics. 
Transition state (TS) mimics have been designed on the premise that the 
enzyme accelerates the cleavage of the scissile bond by binding more tightly to the 
transition state than to the substrate as discussed in Section 1.3.2. above. By 
mimicking the tetrahedral nature of the scissile bond carbonyl carbon at the 
transition state, researchers hope to both enhance binding and substitute a non-labile 
bond to inhibit the protease cleavage. Four major categories of HIV protease 
inhibitors based on transition state mimics are reduced amides, hydroxyethylene 
isosteres, di-hydroxyethylene isosteres and hydroxyethylamines. Each of these 
categories is discussed in detail below. Phosphinates, a,a-diflouroketones, and non-
peptide inhibitors have also been used as tetrahedral TS mimics but were not 
considered as templates for our conformational restriction studies because there is 
no crystallographic information on the bound configuration of these molecules.40 
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1.3.1.1. Reduced amides. 
Compounds like 25 were designed based on the concept that reducing the 
carbonyl of the substrates scissile bond of a substrate analogue prevents cleavage of 
the acyl-nitrogen bond and establishes a tetrahedral center as a TS mimic at the 
carbonyl carbon. Compound 25 (MTV-101) inhibited well enough to give the frrst 
bound inhibitor/protease crystal structure (Ki = 1.4 J.1M), but in general the best 
reduced amide inhibitors exhibit micromolar Ki's.41 More recently, inhibitors with 
the core structure 26 were made and tested by Cushman with Ki's, for the best 
compounds inhibiting at micromolar levels.42 
}-AA i+3 
···y·(·O I NH I NH I NH I 
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OH Ph 
25 26 
1.3.3.2. Hydroxyethylene isosteres. 
Pepstatin (27) is a known inhibitor of aspartic proteases and does exhibit 
moderate activity against mv protease. Early inhibition studies used this 
compound as a standard for inhibition assays, and the Stalin (Sta) unit has been used 
as a transition state replacement in some recent studies despite its relatively poor 
inhibition record (J.1M Ki's at best).43 








Extending the pepstatin backbone of compound 27 by a methylene group to 
fonn a hydroxyethylene isostere maintains dipeptide backbone spacing, and mimics 
the Xxx-Gly dipeptide. The hydroxyethylene isostere 28 is a more effective HIV 
protease inhibitor than the statine analogue by a factor of J03. Compound U-
85548E (29) was found to inhibit HIV protease with K; = 48 nM.44 Later studies of 
this compound showed poor inhibition of HIV protease in cell cultures, but a similar 
compound U-81749 30 was found to exhibit a K; = 70 nM and an IC~0 = 0.1 J.1M in 
cell cultures.45 Dreyer made and conducted HIV protease inhibitor studies on a 
series of substrate analogues with hydroxyethylene isostere inserts. He discovered 
that compound 31 was the best inhibitor with a Ki of 18 nM and that its analogue 
with S stereochemistry at the hydroxyl carbon inhibited better than the R version. 
He proposed that the hydroxyl in the bound inhibitor with S stereochemistry at the 
hydroxyl carbon is positioned between the two aspartate groups at the active site, 
replacing the bound water that would nonnally interact in this position. Apparently 
the R configuration does not mimic this configuration as well.46 
In a most impressive study, hydroxyethelene inhibitors of the type 32 with a 
3-phenylprop-2-ene ligand at Pl' were found to have sub-nanomolar IC50's and 
were active against HIV protease in inhibition studies and in cell cultures. 
28 
Interestingly, compound 32 restricts x2 at Pl •.47 The success of the S configuration 
at the hydroxyl carbon in this compound supports Dryer's proposal above. 
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AMBI = 2- (aminomethyl) benzimidazde 
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The hydroxyethylamine mimic of Phe-Pro is illustrated in compound 33. 
The methylene inserted between the hydroxyl carbon and the nitrogen extends the 
dipeptide backbone by one carbon, but it allows incorporation of normal amino 
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acids at Pl' with N-H hydrogen bonding intact for primary amino acids. Roberts 
rationally designed the hydroxyethlamine analogue 34, which exhibited 
subnanomolar IC50 concentrations, and used this transition state mimic to probe 
active sites on the protease. Based on inhibition studies with a series of 15 
compounds, he determined that a tripeptide was needed for optimum activity. 
There were also indications of a large hydrophobic pocket at S3' (to accommodate 
the decahydroisoquinoline (DIQ). The Asn residue was best at P2, and a benzyl 
substituent was best at Pl. The R configuration at the hydroxyl carbon was found 
to be more effective than the S (opposite of the results for the hydroxyethylene 
examples above).48 Comparison of compound 34 to the hydroxyethylene-based 
compound 31 reveals that 34 has an extra methylene in the backbone between Pl 
and Pl'. This longer backbone chain in the active site area may explain the 
preference for R stereochemistry at the hydroxyl carbon. Research on a series of 
similar compounds incorporating the same transition state isostere as 34 found the 
R configuration to be effective. The report on these compounds concludes that the 
DIQ residue acts as a proline mimic.49 The DIQ can also be considered a cyclic X: 
constraint for the cyclohexyl group in DIQ and the crystal conformation illustrated 
in the article shows a g- conformation for the bound DIQ cyclohexane. 
34 
Rich designed eight analogues of 33 above to mimic the HIV protease 
substrates p 17 and p24. They were tested against similar compounds with statine 
30 
and hydroxyethylene (HEA) isostere inserts. The hydroxyethylamines were found 
to be significantly better inhibitors. 50 In a surprise result, the S diastereomer of the 
most potent of these analogues crystallized selectively with the protease; this result 
is consistent with the superior binding of the S diastereomer relative to the R 
Since this result directly conflicted with Robert's results above, a closer 
investigation ensued. Molecular modeling and analysis of crystal structure indicates 
that the tert-butyl end group of the DIQ in 34, and not the DIQ cyclohexyl moiety, 
binds at the S2' subsite causing a modification of backbone configuration that favors 
the R configuration. 51 The debate over the most effective transition state geometry 
for HEA inserts is still active, but it is apparent that the interactions of residues 
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1.3.3.4. Dihydroxyethylene isosteres. 
HO OH 
···n··· 
Ph 36 Ph 
Abbott designed the symmetrical diamino alcohol 35 and diaminodiol 36 
based on the pseudo-C2 axis of the HIV protease. Both were highly effective when 
acylated with Cbz-Val groups (IC50 = 3.0 nM for 35 and < 0.38 nM for all three 
diastereomers of 36). All of the diaminodiol analogues inhibited HIV in cell 
cultures.52 Ghosh and co-workers have subsequently developed a stereocontrolled 
synthetic route to the diaminodiol dipeptide isostere 36 from D-mannitol. 53 
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Workers at Upjohn stereoselectively synthesized analogues of 37 with 
cyclohexyl, isopropyl or phenyl substitution at R 1 and R2. These compounds 
exhibited Ki's ranging from 1 to 26 nM. Variations in stereochemistry at C2 and 
C3 of the isostere demonstrated that the absolute stereochemistry was vital for 
biological activity. One diastereomer was 30 times less potent than the other three. 
There is however no clearly preferred diastereomer for the dihydroxyethylene 
isostere since three of the four tested inhibited with Ki's around 1.5 nM.54 
o H ~ R 2 Noa = 1-napthoxya- -tyl 
Noa -His_ N H. }_ ~ = Amp= 2-pyridylmethylamine y y NH-De-Amp 
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Overall, dihydroxyethylene (DHE) and hydroxyethylene {HE) isosteres are 
the most promising of the transition state mimics based on performance. The 
interaction of HE isosteres is fairly well understood, but the binding geometry of 
the DHE's is not known. The two hydroxyls may replace one or both the water 
molecules that are normally bound at the active site with a substrate. 
1.4. Bound inhibitor crystal studies. 
X-ray crystal analysis of aspartic proteinase/statine based renin inhibitors by 
Blundell in the late 1980's established two important facts about protease inhibitors 
that have been consistent through all reported HIV protease/inhibitor complexes. 
The inhibitors bind in an extended ~strand conformation in the active site cleft, and 
the hydroxyl of the transition state analogue interacts strongly with the catalytic 
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aspartate residues via hydrogen bonds. 55 These observations have become the basis 
for current rational inhibitor design in renin and HIV protease studies as well as 
other aspartic proteases. We studied five reported HIV protease/inhibitor 
complexes (MTV-10I, A-74704, JG-365, U-85548e, and L-700,4I7) in our design 
process. Coordinates for MTV-101 at 2.3 ~ and A-74704 at 2.8 ~ were made 
available to us by Dr. Alexander Wlodawer at the NCI-Fredrick Cancer Research 
Facility and the Department of Anti-infectious Research at Abbott Laboratories. 
Literature reports on the other complexes were compared to graphical data available 
on MTV-10I and A-74704. 
1.4.1. The MTV-10I complex: A reduced amide isostere. 
This complex of MTV-10I and chemically synthesized HIV-I protease was 
reported frrst at 2.3 A and later at 2.0 ~ resolution_36,56 MTV-10I (Compound 25) 
bound to the enzyme in extended ~strand configuration as indicated in Figure 5. 
Norleucine residues at PI and PI' are extended into hydrophobic pockets at SI and 
S2. De and Gin occupy P2 and P2' respectively, but the Thr residue at P3 is in the 
solvent channel; the Arg at P3' binds to the outside surface of the enzyme. At the 
active site there is no interaction with the enzyme aspartate residues because there is 
no carbonyl or hydroxyl in the TS mimic. 
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Figure 5 
The most interesting aspect of Wlodawer's study was the discovery of 
extensive enzyme conformational changes on binding to an inhibitor. Binding 
caused a hinge motion of 1.7 A with the hinge at the inter-subunit j3-sheet interface. 
This motion tightens the active site cavity. Two flaps extend over the active site 
enveloping the inhibitor as can be seen in figure 6a and 6b. In the native enzyme 
the flap of the bottom subunit is over that of the top. This arrangement reverses in 
the bound inhibitor complex with the tips of the flaps moving more than 7 A. in the 
binding process. A review of the hydrogen bonding interactions in the crystal 
complex indicates no interaction at the active site; this is probably one reason that 




1.4.2. The A-74704 Complex: A diamino alcohol isostere. 
This complex between the two-fold (C2) symmetric inhibitor and the HIV-1 
protease was reported at 2.8 Jt.57 The inhibitor is bound in a stair-step extended ~­
sheet configuration with a rough C2 axis as shown in Figure 7a and 7b (inhibitor in 
green). These figures also accentuate the narrow nature of the enzyme and its 
relatively small size. P3 through P3' residues bind in roughly the same enzyme 
subsites as MTV-101 but are involved in more hydrophobic interactions per Table 
2. The inhibitor has the same number of predicted hydrogen bonds to the enzyme 
as MTV -101 except that hydroxide moiety hydrogen bonds to the active site 
aspartates. The increased number of hydrophobic contacts and the extra hydrogen 
bonding at the active site may explain the lower Ki of A-74704 when compared to 
MTV-101 (4.5 oM vs 700 nM) but the use of different assays tends to confuse this 
argument significantly. Figure 8 demonstrates that the flaps in this complex behave 






















Wlodawer reported an inhibitor!HIV -1 protease complex for JG-365 
(Compound 38) with a 0.24 nM Ki. This inhibitor was also bound to the enzyme in 
an extended ~-strand configuration with stereochemistry at the hydroxyl carbon. 
H- Bonding and hydro!lhobic interactions were found to be better than MTV -10 I. 58 
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Apparently the extra hydrogen bonding by the hydroxyl at the active site and the 
larger benzyl residues at Pl and Pl' afford binding advantage. 
Figure 8 
A crystal structure of pseudo c2 symmetrical compound 39 bound to the 
HIV protease was obtained and reported. This compound exhibited a subnanomolar 
IC50. The crystal structure indicated that the inhibitor formed fewer hydrogen 
bonds to the enzyme than it was capable of forming, but that hydrophobic 
interactions were comparable to examples above. The authors tout "efficient 
packing" of the P2/P2' binding sites by the large indan rings as a hydrophobic 
advantage.59 However, the disrupted H-bonding pattern could be the result of 
backhone configuration changes caused by "over packing" these sites, which 
previously have been found to accommodate only small hydrophohic groups. 
38 
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Tommasselli has reported an HIV protease crystal structure bound to the 
sub-nanomolar hydroxyethylene based inhibitor U-85548e (40). Binding was 
similar to MTV-101 and A-74704, and the HE isosteres general preference for S 
hydroxy carbon configuration was confmned again. Based on the geometry of the 
active site moieties in the complex, a new concerted mechanism was proposed 
involving simultaneous attacks of the nucleophilic water and the electrophilic 
proton per Scheme 3. 
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1.5. Analysis and design of conformationally constrained peptide mimics for mv 
protease binding studies. 
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After reviewing available information on peptide conformational restrictions 
and mv protease inhibition studies above, we decided to investigate substituted 
cyclopropanes as mimics for the P21P2' sites of Abbott's symmetrical diaminodiol 
inhibitor 41. This compound is an attractive base compound for constrained 
analogues because: (I) the HDE isosteres exhibit high binding affmity toward lflV 
protease; (2) the compound's symmetrical nature allows the same changes to be 
made to both ends of the molecule to eliminate binding distortions that could be 
caused by induced fit of the symmetric enzyme to an asymmetric inhibitor; (3) the 
known atomic coordinates of A-74704/HIV protease complex should serve as a 
reasonable P21P2' template for mimic design; (4) the biological activity of 41 and its 
analogues have been extensively studied so a base of information for comparative 
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studies exists; and {5) researchers at Abbott agreed to provide compound 36 as 
starting material. Therefore, design and synthesis of the c-Val mimic of Scheme 4 
and its analogues became the primary focus of this research project. 
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CHAPTER 2. RATIONAL DESIGN OF SUBSTITUTED CYCLOPROPANES 
AS PEPTIDE MIMICS. 
2.1. Introduction. 
It is beyond the scope of this paper to provide a detailed review of molecular 
modeling. Kollman authored a basic review of the subject in 1987,60 and workers 
at Ciby-Geigy prepared an excellent review of software and methods for medicinal 
chemistry in 1990.61 Guidelines for publication of computer studies are set forth in 
the Journal of Medicinal Chemistry.62 Our modeling was done in the SYBYL and 
MACROMODEL molecular modeling programs. The Tripos force field was used 
to model small molecules, and Kollman-united and Kollman-all force fields were 
used to model peptides. 63 Pertinent examples of computer design and analysis of 
inhibitors for aspartate proteases and viridae abound.64 
Our molecular modeling in this project was conducted in three stages. We 
frrst conducted relatively crude computer studies of known inhibitors using the 
enzyme/inhibitor complexes as templates. We then conducted backbone 
configuration analysis and 'X' angle analysis of substituted cyclopropanes before 
proceeding to detailed comparisons of c-Val to the P2/P2' residues of bound 




2.2. Conformational analysis of known inhibitors and the search for "flap water" 
mimics. 
After a three dimensional (3-D) visual analysis of the native protein and the 
MTV -10 1/protease complex. our frrst goal was to determine if the most effective 
inhibitors reported at the time could achieve the configurations necessary to bind 
the HIV protease in a manner similar to MTV -101. For this study the 
hydroxyethylene analogue U-81749 (42) and Rich's best hydroxyethylamine (43) 
were modeled. An RMS fit of both modeled compounds. including backbone 
carbons and CJi carbons from subsite P2 to subsite P2'. was conducted against 
MTV -10 I in its bound configuration. All bonds in inhibitors 42 and 43. including 
amide bonds, were allowed to rotate. The extra backbone methylene in 43 was 
compensated for by not including the scissile bond carbons in the fit so they could 
move as dictated by the "binding" of PI and PI' residues. Results were 
disappointing. Compound 43's best RMS fit to MTV-10I was 0.86 A and an RMS 
fit of 0.40 A was achieved for 42. Both fits also involved some cj) and v angles 
significantly different from the Ji-strand like values observed in MTV -101. One 
bright spot was that all P2-P2' residues in these two inhibitors could be stericly fit 
into the S2-S2' subsites on the enzyme. After a brief attempt to fit a model of 34 
against MTV -I 0 I with similar results, this project was dropped. 
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Substituted quinuclidones 44, cerulinin mimics 45, cerulinin tautomers 46, 
bicyclo[ 1.1.2]hexanone derivatives 47, 3-hydroxycyclohexanones 48, and cyclic 
urethanes 49 were modeled and fit by manually docking them with the A-74704 in 
its bound conformation in an attempt to fmd an active site mimic that could replace 
both the active site nucleophilic water and the water bound between the flaps of the 
inhibitors to enhance binding. None of these fits were attractive enough to warrant 
further study. 
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2.3. Analysis of cyclopropane's effect on conformation. 
As mentioned above, a common trait of bound aspartic protease inhibitors is 
they bind in an extended (3-strand configuration. One graphic example of the 
conserved nature of this binding geometry in aspartic proteases was discovered in a 
preliminary computer analysis of bound inhibitor crystal structures. Rigid RMS fits 
of bound inhibitors such as MTV -101 and A-74704 were found to be generally 
close ( <0.4 A P2-P2' backbone plus c 13 ), but the P2-P2' backbone plus Cp RMS tit 
of Seguna's bound rhizopus pepsin inhibitor and Abbott's aspartic protease bound 
renin inhibitor A-0904 was 0.012 A! A stereoview of this remarkable example of 
conserved backbone orientation is provided in Figure 9. With this encouraging 
discovery behind us we proceeded to local analysis of q, and x angle restrictions by 




2.4. Cyclopropane as a cj>-angle restrictor. 
so 
Compound 50 representing symmetrically trans-disubstituted cyclopropanes 
was fit against the backbone P2-P2' sites of the bound inhibitors MTV-101 and A-
74704 to test the ability of substituted cyclopropanes to mimic the bound inhibitor 
residues cp angles. Results of backbone fits in Table 3 indicated that trans-
substituted cyclopropanes mimic the psuedo-f3-strand conformation of these two 
inhibitors best when incorporated at P2 and P2', and RMS fits of the Ci-1-Ni-Cai-
Ci sequence for cyclopropanes against amino acids in the traditional extended J3-
sheet configuration (cp = -1390,'If = 1350) were all less than 0.12 A. 
Table 3 
RMSAT(A) 
MTV- 101 A-74704 
P2 0.26 0.18 
P1 0.60 0.52 
Pl' 0.42 0.50 
P2' 0.17 0.12 
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These two studies indicated that the P2 and P2' site of an inhibitor would be 
the most attractive position to insert cyclopropane moieties in HIV protease 
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2.5. Cyclopropanes as x angle restrictors. 
The ability of cyclopropanes to match backbone orientation and simulate a 
g- conformation because of the "bent" nature of the cyclopropyl c-c bonds is 
illustrated in Figure 10. The (C) carbon in Figure 10 represents the cyclopropyl C2 
47 
that replaces the amino acid nitrogen when the mimic is inserted into a peptide 
chain. The bent (C) to Ca to C~ bond angle causes the R group to position itself at 
the g· position. Using this analogy we designed substituted cyclopropane mimics 
Sla and b to achieve g+ and g- configurations. We also modeled an anti mimic 52, 
but it is a 'If angle restrictor and has not been considered in the current study. 
Figure 11a and 11b provide stereo views of g· and g+ cyclopropane mimics of Phe 
fit against a Phe in extended (3-sheet configuration with g- and g+ orientations 
respectively. Analysis of P2 X1 angles in the bound configurations of two HIV 








X1 at P2 
g-, anti 
g+(Et), g-(Me) 
These results and visual analysis of the S2 subsite in the HIV protease 
indicates that there are methyl group sized "pockets" at S2 subsite in the g- and anti 
positions of the substrate and a larger "pocket" capable of accommodating an ethyl 
group at the g+ position. Figure 12 compares the orientations of free valine 
(preferred), bound A-70704 and MTV-101 residues, and the c-Val mimic from 
Scheme 4. 
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2.6. Conformationally constrained inhibitor design. 
The Abbott diol 53 was chosen as a template for conformational restriction. 
Compounds 54, 55, 56, and 57 represent a series of potential mimics that could be 
used to probe the HIV protease at the P2 subsite. Compound 54 varies from 53 
only in the replacement of Val with c Val and the use of benzyl end groups instead 
of carboxyl benzyl end groups. The benzyl substituted amide was selected as a 
target over a carboxybenzyl mimic to "add back" the N-H donor lost at C2 of the 
cyclopropyl mimic and give 54 the potential to establish the same number of 
hydrogen bonds as 53. This compound is expected to test the validity of the c-Val 
mimic as a replacement for Val at P2 and P2' in HIV inhibitors. Compound SS 
differs from 54 by a cis configuration at cyclopropane. It is designed to validate the 
molecular modeling prediction of superior binding by trans-substituted compounds 
over cis-substituted compounds. Compounds 56 and 55 are designed to investigate 
the effect of replacing hydrophobic end groups with hydrophilic end groups on 
binding and transport. 
The c-Val mimic should simulate the required backbone configuration of 
Val in the bound inhibitor and achieve an entropic binding advantage while 
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matching the hydrophobic binding potential of Val with methyl groups in 2 of the 3 
P2 "pockets" described above. Synthetic routes to these mimic compounds are 
discussed in detail in Chapter 2. 
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CHAPTER 3. SYNTHESIS OF SUBSTITUTED CYCLOPROP ANES AS 
PEPTIDE MIMICS. 
3.1. Introduction. 
Each of the HIV protease inhibitors we uesigned in Chapter 2 has eight chiral 
centers and to properly evaluate the effects of the substituted cyclopropyl peptide 
mimics on HIV protease inhibition, compounds 53 through 57 must be 
diastereomerically pure. The establishment of eight chiral centers represents a 
significant synthetic challenge. Fortunately, the symmetrical nature of the molecule 
allows the use of the same P2-end group mimic on each end of the inhibitors, and 
researchers at Abbott Laboratories have established four of the chiral centers in the 
enantiomerically pure diamino diol compound 36 that they provided to us. Our 
challenge was reduced then to the establishment of only two chiral centers for the 
tetrasubstituted c-Val mimics and three chiral centers for 1 ,2,3-trisubsutituted 
analogues of c-Val. 
We based our synthetic scheme for the HIV protease inhibitors 53 through 
57 on the enantioselective Rhodium(ll) [Rh(ll)] catalyzed intramolecular 
cyclopropanation reactions exploited by Martin and Austin in their synthesis of renin 
inhibitor N-terminal-P3 replacements 21 and 22.65 Our synthesis of substituted 
cyclopropyJ peptide mimics involves the same steps that were used to afford 
compounds 21 and 22: (1) enantioselective cyclopropanation; (2) opening of the 
resulting cyclopropyl lactone; (3) epimerization at one of the cyclopropyl carbons 
(for trans mimics only); and (4) oxidation of the hydroxyl or aldehyde Cl 
51 
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substituent. Coupling the resulting mimics to the Pl-Pl' transition state insert 36 
completes this short and enantioselective route to the targeted inhibitors. 
This chapter provides a review of recent work involving chiral Rh(II) 
catalysts and the application of these catalysts to synthesis of substituted 
cyclopropanes as peptide mimics. Our synthetic scheme, results and general 
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3.2. Enantioselective Rh(II) catalyzed cyclopropanations. 
Intramolecular and intermolecular cyclopropanation reactions of 
diazoacetates and olefms have been catalyzed by Cu, Ag, Fe, Rh, Re, Mo, and Co 
complexes, but stereo- and enantioselectivity in these reactions were not achieved 
until the advent of chiral copper catalysts by Noyori in 1966.66 Since this seminal 
study, enantioselective cyclopropanation has been achieved with chiral copper, 
53 
cobalt, and rhodium catalysts.67 Doyle compiled an excellent review of stereo- and 
enantioselective cyclopropanations that have been catalyzed by transition metal 
complexes. In this review he concludes that the chiral Rh(ll) catalyzed 
intramolecular cyclizations of the type that we have selected for our synthetic 
scheme are among the most synthetically promising of the chiral TMC catalysts.68 
3.2.1. Chiral rhodium(ll) carboxylate catalyzed cyclopropanations. 
Doyle reported in 1986 that rhodium acetate would catalyze a variety of 
reactions via carbenoid intermediates derived from diazoacetate decomposition.69 A 
natural outgrowth of this discovery was the investigation of chiral amino acids as 
potential ligands for enantioselective catalysts. Two studies involving amino acids 
and amino acid analogues as ligands in Rh(ll) carboxylate catalysts have been 
conducted. Brunner evaluated thirteen Rh(ll) complexes of the type Rh2(00CR*)4 
containing optically active carboxylic acids in the reaction of ethyl diazoacetate and 
styrene in Scheme 5.70 Diastereoselectivity was poor for all the catalysts, and 
mixtures ( 1:1) of cis: trans isomers were invariably obtained. Enantioselectivity was 
also poor with the enantiomeric excess (ee) of the products below 7% for all 
catalysts except compounds 58 and 59 that achieved product ee's of 12% and 10% 
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McKervey in a study of the intramolecular cyclopropanation used (S)-
mandelare as a ligand to prepare dirhodium TMC catalyst 60 which produced a 12% 
ee of product 61. One encouraging result in this study was the 97% yield of 
compound 61.71 The accepted explanation for the poor selectivity of chiral 
rhodium(II) carboxylate catalysts is that the large distance (d) between the carbene 
formation site and the chiral center in the carboxylate precludes significant 
interaction between the ligands and the carbenoid per figure 12. 
Figure 12 
3.2.2. Chiral rhodium(II) carboxamide catalyzed cyclopropanations. 
Doyle synthesized chiral rhodium(II) oxazolidinones 63, 64, and 65 in 
Figure 13. He observed higher enantioselectivity in the intermolecular 
cyclopropanations of styrene and optically active 1-menthyl diazoacetates with these 
catalysts than was observed with chiral carboxylate TMC catalysts. In the 
55 
intramolecular reaction of Scheme 7, the TMC catalysts 63, 64, and 65 all produced 
yields of near 50% withee around 50%. 
SCHEME7 
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Carbene dimer and butenolide 68 are formed in major side reactions with 
yields of compound 68 reaching 12% with the R version of TMC catalyst 64.72 
Doyle also found that chiral rhodium(ll) carboxamides are less reactive towards 
diazocompounds than rhodium(ll) carboxylates, and he has postulated that they are 
more enantioselective because they move the ligand chiral center nearer to the 
carbenoid center. 
63 R1 =iPr.~=H 
63 R1 =Bn.~=H 
Figure 13 
65 
The dirhodium(II)tetrakis-(alkyl-2-pyrrolidinone-5-carboxylate) catalysts, 
depicted in theirS and R configurations in Figure 14, produced much better results 
than compounds 63, 64, and 65 in intramolecular reactions of allyl diazoacetates. 
Doyle has attributed the better performance of these carboxamide catalysts to 
56 
orientation and stabilization of the bound electrophilic carbene, .- the polar 
carbonyl oxygen of the ester substituent in compounds 69, 70 and 71. 
J\ otH O~NAcooR 
1/ I/ 
Rh-Rh /1 _......, 
69a R =Me ~ (5S-MEPY)J 
70a R = iPr [~ (5S-IPPY)J 
71a R = neoPent ~ (5S-NEPY)J 
f\ ·•COOR OAN~ 
1/ 1......-
Rh-Rh /1 _......, 
69b R =Me ~ (5R-MEPY)J 
70b R = iPr ~ (5R-IPPY)J 
71b R=neoPent ~(5R-NEPY)J 
Figure 14 
Doyle has postulated that the polar ester substituent directs backside attack of 
the nucleophilic olefm on the side of the carbene opposite the stabilizing ester 
function per Figure 15. The least sterically congested of the two complexes in 
Figure 15 is expected to predominate. One example directly applicable to this 
research project is displayed in Figure 16, in which the orientation of the 3-methyl-
2-butene-1-yl carbenoid complex is stabilized by the top carbonyl as in Figure 15a 
and the terminal carbon of the olefm is pointed out from the carbene center in the 






Enantioselectivity in intramolecular cyclopropanations of allyl diazoacetates 
as catalyzed by compound 69 is reviewed in Table 5 below. Examination of the 
carbenoid complex conformation in Figure 16 indicates that the higher 
enantioselectivity observed in Table 5 for Z olefms over E olefins is due to steric 
crowding between the olefm substituent and the ester functionality of the bottom 
ligand.73 
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3.2.3. Application of chiral rhodium(II) carboxamide catalysts to the synthesis of 
1,2,3-trisubstituted cyclopropanes as novel dipeptide isosteres. 
Martin and Austin designed compounds 21 and 22 and developed the novel 
enantioselective trisubstituted cyclopropane synthesis depicted in Scheme 8. The S 
configured rhodium(II) catalyst 69a is used in Scheme 8 but, antipodes of the 
optically active compounds in this scheme are accessible by catalyzing the 










.. X R1 ~ ~ 
Rl R2 "(%} Yi~h;l(%} 
H H 88 74 
H Ph >94 45 
H Et >94 88 
H Bn >94 80 
H SnBu3 >94 78 
Me Me 92 82 
Ph H 65 59 
Pr H 75 74 
H iBu 93 71 
The crucial reactions in this scheme are the TMC catalyzed 
cyclopropanation, which sets three chiral centers in greater than 90% ee and the 
opening of the resulting lactone with dimethylaluminum amides via a procedure 
developed by Weinreb. Both proceed with excellent yields and provide points of 
flexibility in the synthetic scheme. The route to 21 and 22 exploited the 
enantioselectivity of the catalyst at the cyclopropanation step by using R and S 
versions of the catalyst, but the flexibility inherent at the Weinreb reaction step was 
not investigated as part of this synthesis. 
OH 







3.3. Enantioselective synthesis of substituted cyclopropane and incorporation into 
peptides and pseudopeptides. 
3.3.1. Retrosynthetic analysis and synthetic scheme. 
A general retrosynthetic analysis of our targeted mv protease inhibitors is 
set forth in Scheme 9. This scheme illustrates how the combined flexibility of the 
cyclopropanation and the Weinreb opening steps allows possible synthetic routes to 
an almost unlimited number of compounds. The MJ series of compounds 54-57 and 
76-83 are designed to determine the efficacy of substituted cyclopropanes as P2/P2' 
mimics in inhibitors of the HIV protease. Compounds 54-57, when synthesized and 
tested, will allow comparison of: (1) cis and trans backbone effects; (2) D to L 
amino acid mimic effects; and (3) hydrophilic to hydrophobic end group 
performance. 
60 
The flexibility of the MEPY catalyst combination is summarized in 
Scheme 10. The cyclopropyl carbons are designated a, b, and c based on the amide 
alcohol structure as specified. Both Land D amino acid mimics (L-Xxx and D-Xxx) 
are available from either catalyst depending on which backbone carbon is 
epimerized. 
In addition to the flexibility already mentioned, the Weinreb opening step 
offers the ability to select the C- or N-terminus orientation of the cyclopropyl mimic. 
Opening cyclopropyl lactones with the dimethylaluminum amide of an alkyl 
substituted primary or secondary amine results in a mimic in which Ca represents the 
Ca amino acid carbon. Opening with the dimethyl aluminum amide of an amino 
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MJ-1 s s Me Me H Bn 54 
MJ-2 R s Me Me H Bn 55 
MJ-3 R R Me Me H Bn 76 
MJ-4 s R Me Me H Bn 77 
MJ-5 s s Me Me [MORPH] 56 
MJ-6 R s Me Me [MORPH] 57 
MJ-7 R R Me Me [MORPH] 78 
MJ-8 s R Me Me [MORPH] 79 
MJ-9 s s Me Me Bn Bn 90 
MJ-10 R s Me Me Bn Bn 81 
MJ-11 s s s H Et H Bn 82 
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3.3.2. Synthesis: Results and discussion. 
The synthetic scheme we followed to compound 56 is set forth in Scheme 11 
and represents the general route used in progress toward HIV inhibitors 53 through 
57. Bis-(N-tert-butylsalicyladiminato) copper(ll) catalyst {Cu(TBS)2 } was prepared 
by the published procedure with a 72% yield. 74 Rh{ll) catalysts were prepared in 
63 
prepared in accordance with methods developed by Doyle. 73 Results for each step 







3.3.2.1. Preparation of alkyl diazoacetates. 
Two routes to the desired allylic diazoesters were investigated. Scheme 12 
represents the transformation of allylic alcohol 91 to allyl diazoacetate 66 via 
diketene addition, diazotransfer, and deacylation.75 Poor yields and the formation of 
product mixtures in the deacylation ste!' prompted us to use the more efficient 
procedure of Schemes L; ,_:rJ 14.76 The glyoxylic acid chloride p-toluenesulfonyl 
hydrazone 95 was easily prepared ir. large qu;mtities77 ru1d was coupled smoothly 
with allylic alcohols 91 and 96 when treated with N,N-dimethylaniline and 
triethylamine in dichloromethane. The literature procedure called for an excess of 
95 (1.8 equiv) but one equivalent of 95 afforded yields of over 90%. The yellow 
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The intramolecular cyclization of compounds 66 and 97 was catalyzed by the 
Cu(II) catalyst 90 in accordance with published procedures to afford racemic 
mixtures 98 and 99 with yields of over 70% . 74 Both products were found to be 






97 R1 =H.~=Et 
SCHEME 15 
Cu(TB5) 2 ,. (fo 
R1 R2 
98 R1 .~=Me 
99 R1 =H.~=Et 
Intramolecular cyclizations per Equations (I) and (2) of 66 and 97 with 1 
mole percent of Rh(Il) catalyst 69a in methylene chloride proceeded smoothly with 
yields of 80% and 94% to afford cyclic lactones 67a and 74a, respectively. The 
enantiomers of the above S-MEPY reaction products, 67b and 74b, respectively, 
were obtained via catalytic cyclization of 66 and 97 using the R-MEPY catalyst 
69a.73 Cyclic lactone 67a was optically active with [c:xhs = +64.40 and its 
enantiomer 67b exhibited [ c:xh5 = -520. A variation in the optical purity of the 
catalysts used in the cyclopropanations may explain the discrepancy in absolute 
values of optical rotation for 67a and 67b. The S catalyst had been purified by flash 
chromatography and recrystallization and the R catalyst used had been purified only 
by flash chromatography and may have been less optically pure than the S version. 
Overall the Rh(ll) catalytic transformations provided clean and efficient routes to 
optically active materials. 
67 
0 /0~0 ~ - -:. = Jo ~ Rh 2 (5S-MEPV) 4 R1~ .. CH 2 CI 2 Eq (1) R1 ~ 
66 R1 .~=Me 67a R1 .~=Me 
97 R1 =H.~=Et 74a Rl =H,R2=Et 
0 9:0 Jo\ Rh 2 (5R-MEPV) 4 Eq (2) .. CH 2 CI 2 
R1 ~ R1 ~ 
66 Rl,R2=Me 67bR1 .~=Me 
97 Rl = H , R2 = Et 74b R1 =H.~=Et 
3.3.2.3. Opening cyclopropyllactones with dimethylaluminum amides. 
Cyclopropyl lactones 67a, 74a, and 67b were converted to amide alcohols 
86, 100, 101, 102, and 103 in accordance with Weinreb's general procedure for 
amimolysis of esters by treatment with trimethylaluminum amides of morpholine, 
benzylamine, and dibenzylamines per Equations (3) through (5).78 Reactions using 
benzylamines proceeded in good yields (70-80% ). Morpholine reactions, however, 
were less efficient with yields consistently below 60%, and reactions using 
dibenzylamine afforded very poor yields ( 10% ). Attempts to improve yields in the 
Weinreb procedure for secondary amides by raising reaction temperature from 
refluxing methylene chloride (44 OC) to refluxing 1,1,1-trichloroethane (TCE) 
and/or increasing the reaction time to >36 h were unsuccessful. It should be noted 
that the hydroxyl carbon (Ca) in the amide alcohols of Equations (3) through (5) is 









Me 2 AIN, 
---•R2 
2) aq. HCI 
1) Me 2 AI NHBI 
• 
2) aq. HCI 
2) aq. HCI 
86R1 .~=(~~ 
100R1 =H, ~=Bn 
101R1 .~=Bn 
OH 0 











We developed a novel modification of the Weinreb procedure that 
incorporates the cyclopropane into a peptide chain and reverses the directionality of 
the amide alcohols. Equations (6) through (8) detail reactions of this type in which 
excess trimethylaluminum (6 equiv) is treated with an amino acid in methylene 
chloride before adding the cyclopropyl lactone. Yields obtained in refluxing 
methylene chloride were low, (10-20%), but increasing the reaction temperature by 
refluxing in TCE and the reaction duration from 24 to 36 hours dramatically 
improved yields to over 70%. The amide carbon (Cb) of the cyclopropyl moiety in 
104-106 is in the direction of the C-terminus of these dipeptide mimics and the 
hydroxyl carbon (Ca) is at the N-terminus. This reaction, therefore, offers the ability 
to control the C-terminus directionality of a substituted cyclopropane by opening a 
given cyclopropyl lactone with either an amine or an amino acid. 
69 
OH 0 [~ /0~0 CH2Clz 1 -~ - 1) Me 3 AI/ phe : 
.. ~x-bNH C02H 
:X 2) aq. HCI Eq (6) 10% 
67a 104 
0 TCE ~~·S'" / ~0 1)Me 3 AI/pro 0 = .. Eq (7) 
. :X 2) aq. HCI 76% 
67a 105 
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2) aq. HCI avb 
74~r 74% uw;'f 
3.3.2.4. Epimerization at Ca and Cb in substituted cyclopropanes. 
Epimerization of Cain the morpholine derivative 86 vvas accomplished by 
converting the amide alcohol to amide aldehyde 87 followed by treatment with 
potassium carbonate in methanol to yield the trans amide aldehyde 88 
[Equation(9)].79 Attempts to convert the cis amide alcohol 100 to an aldehyde via 
PCC oxidation (3 equiv) resulted in formation of imide 107 as the exclusive product 
per Equation (10). Reducing the amount of PCC (1 equiv) did not stop the 
cyclization. A similarly discouraging result accompanied our one attempt to oxidize 
the alcohol in pseudodipeptide 104 to an aldehyde with PCC. NMR analysis of 
reaction products of this oxidation indicated that oxidative decarboxylation of the 
amino acid may have occurred. Swern oxidation was considered as a method of 
oxidizing alcohol 100, but it was not attempted because it was also expected to result 
70 
in formation of imide 107 and the option to establish trans substituted configurations 
by epimerization of Cb still existed. 
OH 0 0 0 0 0 
1 ~N1 H) _-llN1 "~~o - PCC i<:zC03 x ~0 .. X l~o .. Eq (9) c~c~ CHaOH 
86 64% 87 90% 88 
Bn 
OH 0 I ~ lNH81 PCC oYNYo 
x ... /;;z CH2C~ Eq (10) 
/ ""' 
100 53% 107 
Cyclization with R-MEPY catalyst 69b in the initial cyclopropanation step 
and epimerization at Cb would still allow access to the benzyl substituted L-valine 
mimics necessary to obtain potential inhibitor 54. We first attempted to epimerize 
the secondary amide alcohols 100 and 102 by treatment with three equivalents of 
lithium hexamethyldisilizide (LiHMDS) per the conditions in Scheme 14a. Some 
starting material was recovered but the epimerization to compounds 108 and 109 did 
not occur.65 The same reactions with four equivalents of LiHMDS also afforded 
starting material. Assuming that the formation of a stable dianion precluded the 
desired epimerization, we set out to protect both the hydroxyl and amide functions of 
compounds 100 and 102 before treatment with LiHMDS. Attempted catalytic 
trimethylsilylation of both functional groups with HMOS and saccharin (Sacc) per 
Scheme 14b resulted in silylation at the alcohol only to form compound 108b.80 To 
71 
alleviate the possibility that the catalytic silylation product was silylated at nitrogen 
with a highly labile TMS group that was lost in the work up, we carried the crude 
reaction mixture of the silylation step directly through to the epimerization step per 
Scheme 14c and again retrieved only starting material. 
100R1 .~=Me 
102 R1 =H.~=Et 
SCHEME14 
Conditions 
a: 1) 3equivLiHMDS 
2)~0 
108aR1 .~=Me.~=H 
108b R1 , ~=Me,~= 1MS 
109 R1 =H.~=Et 
b: 1) HMDS/SA<r/GI 2CI 2 
c: 1) HMDS I SA<r I ~02 
2) LiHMDS 
3) ~0 
Trimethylsilylation of both functional groups on 100 and 102 was then 
attempted with trimethylsilylchloride (TMSCl), triethylamine (TEA), and a catalytic 
amount of dimethylaminopyridine. The hydroxyl was silylated again, but there was 
no evidence of amide silylation. Only starting material was recovered when the 
crude reaction mixture of the silylation step was carried through the epimerization 
step without isolating the intermediate protected compound. Failure to epimerize at 
either Ca or Cb in compound 100 prevented synthesis of the trans substituted, 
secondary amide acid 110. This precluded preparation of inhibitor 54, but did not 
affect our routes to inhibitors 55, 56 and 57 which are described below. 
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3.3.2.5. P2/P2' peptide mimics. 
Oxidation of amide alcohols 100, 86, 88, 103 and 102 with Jones reagent 
yielded dipeptide mimics 89 and 111-114 per Equations (11) through (15). 
Investigation of the relatively low yields for secondary amide acids 111, 113 and 
114 as compared to the tertiary amide acids 89 and 112 revealed that cyclization to 
form imide 107 was a significant side reaction. Imide yields of up to 21% were 
observed in the oxidation of secondary benzyl amides. Successful oxidation of 
compounds 113, 86, ar.d 88 completed the synthesis of three of the four peptide 
mimics designed in Chapter 2. 
3.3.2.6. Synthesis of HIV inhibitors 56 and 57. 
The first step in the coupling of the dipeptide mimics with 36 was 
deprotection of the N-benzyloxycarbonyl (Cbz) protecting groups of compound 114 
per Scheme 16. Pearlman's catalyst Pd(OH)z (10% on C) effected almost 





Ph 36 Ph 114 
Our initial attempt to couple dipeptide mimics with 36 followed the coupling 
procedure used by researchers at Abbott in which N-hydroxysuccinimide (NHS) and 
N-ethyl-N-(dimethylaminopropyl)-carbodimide (EDC) were used as coupling agents 
74 
agents to prepare Abbott's diol inhibitor 53 from diol 36 and Cbz protected valine. 82 
The Abbott researchers had used the general procedure of Scheme 17 on a relatively 
large scale (3.4 g). An attempt to couple 89 with 36 by this procedure on a small 
scale ( 10 mg) resulted in less than 10% conversion to the desired intermediate NHS 
compound, as determined by NMR analysis of the reaction product mixture. The 
dipeptide mimic 111 was carried through the coupling procedure of Scheme 17 
without isolation ot the NHS ester compound but only starting materials were 
isolated after the reaction. Concerned by our inability to successfully scale down the 






R1 0 0 
Literature research revealed that 1-hydroxybenzotriazole (HOBT) and 
dicyclohexylcarbodimide(DCC) were effective amino acid coupling agents in small 
scale reactions so the HOBTIDCC coupling procedure was attempted on compounds 
114 and 36. The reaction, however, resulted in numerous products, and the mixture 
was too complex to analyze. The HOBTIEDC coupling system used by Abbott in 
coupling 1 ,2,3-trisubstituted cyclopropyl peptide mimics to renin inhibitors was then 
attempted per Scheme 18 and 19. This procedure worked and products 56 and 57 
were identified by low and high resolution mass spectrometry (CI) and crude proton 
and carbon NMR. Purification of these highly polar compounds by flash 
75 
chromatography was not possible for lack of an appropriate solvent system with 
which to elute them on a small scale. Several attempts at recrystallization have 
improved the purity of compound 56 and we are currently synthesizing inhibitor 56 
on a larger scale. Once purified these compounds will be submitted to Abbott 
Laboratories to be assayed for biological activity. 
SCHEME 18 
Ph -~-/0 
O ~ 1) HOBT/NMN/36 ~O .l \t(~H NH ,, -- \_} 
,,, ~N .· NH - ~· 
~_)N ,. OH Jlo \ _) ___ 6H 0 0 ~ 2)EDC 0 -_ Ph 
89 56 
SCHEME19 
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57 124 
3.4 Conclusions. 
The goal of this project was to design and enantioselectively synthesize 
substituted cyclopropanes as dipeptide mimics to insert at the Pl/P2 position of 
inhibitors of the HIV protease. Two of the four targeted inhibitor complexes, 56 and 
76 
57, were synthesized and are being purified for biological assay. Rational synthetic 
routes to inhibitors 55, 76 and 82 were established. 
In addition to achieving the synthetic goals above, some preliminary 
questions pertaining to the chemistry of tetra- and trisubstituted cyclopropanes have 
been answered. In particular, it was discovered, that the Weinreb procedure 
provides an effective route to cis substituted secondary amide cyclopropyl alcohols. 
It was also discovered that the cis to trans epimerization techniques previously 
developed for tertiary amide alcohol compounds could not be applied directly to 
their secondary amide analogues. Intramolecular cyclization of these secondary 
amide compounds complicated PCC and Jones oxidations. On a more positive note, 
a novel and effective route to dipeptide mimics containing substituted cyclopropanes 
was discovered in the amino acid modification of the Weinreb procedure. 
Two major questions in this study require continued investigation. 
First, the ability to epimerize either Ca or Cb, and preferably both, in the secondary 
amide substituted cyclopropane series is crucial to the effective use of our TMC 
catalyzed intramolecular cyclization scheme. One attempt to protect the amide 
nitrogen with a benzyl group prior to oxidation in the Ca epimerization scheme 
foundered in the poor yields of the dibenzylamine Weinreb reaction. Our attempts to 
protect the mimic's hydroxyl and amide functions with a trimethylsilyl group, by a 
variety of methods, resulted in silylation of only the alcohol in every case. One 
potential solution to the epimerization problem is N silylation with tert-
butyldimethylsilyl (TBDMS) which has proven more effective in protection of 
nitrogen than TMS. 83 For the Ca epimerization scheme, nitrogen protecting groups 
such as Cbz could prove effective in preventing cyclization, and recent results by 
77 
workers in our group indicate that the Swem oxidation conditions may prevent 
complete cyclization of the aldehyde to the imide. Second, the question of effective 
small scale purification methods for highly polar compounds such as 56 and 57 is 
still unresolved. The compounds adhere to silica and smear in TLC studies in a 
variety of solvents and have defied small scale recrystallization attempts. We are 
continuing to research these two problems and expect to resolve them in the near 
future. 
This research project has expanded our knowledge of the chemistry of 
substituted cyclopropanes and established a synthetic route to potential HIV 
inhibitors with substituted cyclopropanes at the P2/P2' sites. We are now in position 
to exploit this synthetic route to prepare a series of mv protease inhibitors for 
molecular recognition studies. 
CHAPTER 4. EXPERIMENTAL PROCEDURES. 
Unless otherwise noted, all starting materials were obtained from commercial 
suppliers and were used V'ithout farther purification. Solvents were dried according 
to established procedures by distillation from an appropriate drying agent under an 
inert atmosphere. Tetrahydrofuran (THF) and diethyl ether (Et20) were distilled 
from potassium/benzophenone ketyl under nitrogen prior to use. Benzene and 
toluene were distilled trom and stored over sodium. Dichloromethane (CH2CI2) 
1,1, 1-trichloroethane (TCE) and N,N-dimethylaniline (DM .-\) and triethylamine were 
distilled from calcium hydride under nitrogen immediately prior to use. N,N-
dimethylformamide (DMF) was distilled from calcium hydride immediately prior to 
use. Methanol (MeOH) was distilled from magnesium methoxide immediately prior 
to use. Reactions involving air or moisture sensitive reagents or intermediates were 
performed under an inert atmosphere of nitrogen or argon in glassware that had been 
oven and/or flame dried. 
Melting points were determined on a Thomas-Hoover melting point 
apparatus and are uncorrected. Infrared (IR) spectra were recorded with a Beckman 
Acculab 8 spectrometer either neat, KBr pellet, or as solutions in the solvent 
indicated and are reported in wavenumbers (cm-1) referenced to the 1601.8 cm-1 
absorption of a polystrene film. Proton (1H) nuclear magnetic resonance (NMR) 
spectra were obtained on either a Brucker AC-250 (250 MHz) or a General Electric 
QE-300 (300 MHz) spectrometer as solutions in CDCI3. Chemical shifts are 
reported in parts per million {ppm, d = 0.0). Coupling constants are reported in hertz 
(Hz) with an accuracy of± 0.2 Hz. Spectral splitting patterns are designated as s, 
7X 
- -- ·- ---- ------
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singlet; br, broad; d, doublet; t, triplet; q, quartet; m, multiplet; comp, complex 
multiplet. Carbon (Be) nuclear magnetic resonance spectra were obtained on a 
Brucker AC-250 (62 MHz) spectrometer as solutions in the designated solvent. 
Chemical shifts are reported in parts per million (ppm, O) downfield from TMS (0 = 
0.0) are referenced to the center line of the CDC13 triplet (O 77.0). Percent yields are 
given for compounds that were ~ 90% pure as judged by NMR. Low resolution 
chemical ionization mass spectra (CIMS) were obtained with a Finnigan TSQ-70 
instrument. High resolution measurements were made with a VG Analytical ZAB2-
E .. 
Analytical thin layer chromatography (TLC) was performed on Analtech 250 
micron silica gel GHLF plates (2.5 em x 0.5 em) eluting with the solvents indicated. 
The plates were visualized with short wave UV light and phosphomolybdic acid. 
Flash chromatography was performed according to published methods with 1 Merck 
silica gel 60 (230-400 mesh ASTM). 
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3-methyl-2-butenyldiazoacetate (66). The p-toluenesulfonylhydrazone of 
glyoxylic acid chloride (4.00 g, 15.4 mmol) was added to an ice-cooled solution of 
3-methyl-2-butene-1-ol (1.29 g, 15.0 mmol) in dry CH2Cl2 (45 mL) at 0 OC. N,N-
Dimethylaniline (2.04 g, 1.92 mL, 16.9 mmol) was added, and the solution was 
stirred for 15 min before adding triethylamine (5.60 g, 5.8 mL, 46.2 mmol). The 
resulting suspension was stirred for 15 min at 0 oc and 15 min at room temperature 
before quenching with water (32 mL). The reaction mixture was concentrated in 
vacuo and then diluted with saturated citric acid (32 mL) and a mixture of 
hexanes/EtOAc (9: 1) (32 mL). The organic layer was separated and washed with 
saturated citric acid (2 x 32 mL). The combined aqueous layers were washed with a 
mixture of hexanes/ EtOAc (9: 1) ( 1 x 35 mL). All organic layers were combined, 
dried (MgS04) and concentrated in vacuo. Compound 66 was isolated by flash 
chromatography ( hexanes:EtOAc, 20:1) as a yellow oil, 94% yield; IH NMR (250 
MHz) B 5.38-5.32 (m, 1 H, C2-H), 4.75 (s, 1 H, C2-H}, 4.67 (d, J = 7.2 Hz, 2 H, 
C1'-H), 1.76 (s, 3 H, C4'-H), 1.72 (s, 3 H, C5'-H); nc NMR (62.5 MHz) B 167.5, 
139.3, 118.5, 61.6, 46.1, 25.7, 17.9; IR (neat) 3080, 2910, 1690, 1618 cm-1; MS 
(Cl) mlz 154.0728 (C7H10N202 requires 154.0742) 154, 153(base), 152. 
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6,6-dimethyl-3-oxabicyclo[3.l.O]hexan-2-one (98) (racemic). Diazoester 
66 (20 mg, 0.13 mmol) in dry toluene (10 mL) was added via syringe pump to a 
refluxing solution of bis-(N-t-butylsalicyladiminato)copper(II) (90) (2 mg, 0.06 
mmol) in toluene (15 mL) over a period of 10 h. The reaction was concentrated in 
vacuo, and the residue was purified by flash chromatography (ether/pentane, 1:1) to 
afford compound 98 (12 mg, 0.095 mmol) as a clear yellow oil. 74% yield; IH 
NMR (250 MHz) o 4.37 (dd, J = 5.4, 9.9 Hz, 1 H, C4-H), 4.15 (d, J = 10.0 Hz. 1 H, 
C4-H), 2.07-2.03 (m, 1 H, C5-H), 1.61 (d, J = 4.6 Hz, 1 H, C1-H), 1.18 (s, 3 H, C7-
H), 1.17 (s, 3 H, C8-H); 13C NMR (62.5 MHz) o 174.9, 66.5, 30.5, 30.0, 25.1, 23.0, 
14.3; IR (neat) 2890, 1745, 1450, 1350 cm-1; MS (CI) mlz 127.0760 (C7H110 2 
requires 127.0759). 
General procedure for the cyclopropanation of the allyldiazoacetates 66 
and 97 in the presence of chiral rhodium (ll) catalysts 69a and 69b. A solution 
of the diazoester in dry CH2Cl2 (0.1M) was added via syringe pump to a refluxing 
solution of the catalyst (0.01 equiv) in CH2Cl2 (0.001 M) over a period of 8 h. The 
reaction was cooled to room temperature and concentrated in vacuo, and the residue 





Prepared using Rh2(5-S-MEPY) catalyst 69a. The crude residue was purified to 
afford compound 67a ( 179 mg) as a clear oil. 94% yield; 1 H NMR, nc NMR, IR, 
and MS spectra are identical to the racemic 98 above; [a]f>21 = +64.4 (c = 1.20, 
CHCl3). 
3 
£0 0 4 1 7/ 8 
[ lR-(1 a,Sa) ]-6,6-dimethyl-3-oxabicyclo[3.l.O]hexan-2-one( 67b ). 
Prepared using Rh2 (5-R-MEPY) catalyst (69b). The crude residue was purified to 
afford compound 67b (145mg) as a clear oil. 79% yield; 1H NMR, Be NMR, IR, 
and MS spectra identicnJ to 67a and 110 above. [<X]o21 = -51.8 (c = 1.01, CHCl3). 
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General procedure for opening lactones to amide alcohols. A 2.0 M 
solution of trimethyl aluminum in hexanes (3 equiv) was slowly added at room 
temperature to a solution of the amine (3 equiv) in dry CH2Cl2 (0.40 M). The 
mixture was stirred for 10 min .• and a solution of lactone (1 equiv) in CH2Cl2 (0.35 
M) was added. The reaction was heated at 44 oc for 28 h, cooled to 0 oc, and 
carefully quenched with 2.5 N HCI (1 volume). The reaction mixture was extracted 
with CH2CI2 (3 x 1 volume), dried (MgS04), and concentrated in vacuo. 
OH 0 
l"t --=-~ 1' 2' 3' i·r: NH~·· 
-_ Ty5' 6 -_ 5 
- 6 
[1-S-(1a,2a)]-2-(Hydroxymethyl)-1-(4-benzylaminylcarbonyl)-3,3-
dimethylcyclopropane (100). Prepared by opening lactone 67a with benzylamine 
as the amine per the general procedure above. The crude residue was purified by 
flash chromatography (EtOAc/hexanes 6:4) to afford compound 100 (81 mg) as 
viscous yellow oil. 70% yield; lH NMR (250 MHz) o 7.37-7.26 (comp, 5 H, C3'-
C7'-H). 6.21 (br s, 1 H, N-H), 4.35 (d, J = 5.7 Hz, 2 H, C1-Cl'-H), 3.98 (dd, J = 6.4, 
12Hz, 1 H, Cl'-H), 2.77 (br s. 1 H. 0-H), 1.44- 1.31 (comp, 2 H, Cl, C2-H), 1.19 
(s, 3 H, C5-H), 1.18 (s, 3 H, C6-H); l3C NMR (62.5 MHz) o 171.3, 138.5, 128.7, 
127.7, 127.4, 59.0, 43.8, 32.5, 31.8, 28.6, 24.0, 15.4; MS(CI) mlz 233.1424 
(C14H19N102 requires 233.1416) 234,216, 155, 154 (base), 136. 
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[ 1-S-( 1 a,la)]-2-(Hydroxymethyl)-1-( 4-benzylaminylcarbonyl)-3,3-
dimethylcyclopropane (103). Prepared by opening lactone 67b with benzylamine 
as the amine per the general procedure above. The crude residue was purified by 
flash chromatography (EtOAc/hexanes 6:4) to afford compound 103 (27mg) as a 
viscous yellow oil. 70% yield; Be NMR spectrum identical to 100 above; the lH 
NMR varies only in the position of the hydroxyl hydrogen at o 2.14 (br s, 1 H) vice 
2.77. MS (CI) mlz 233.1406 (Ct4H19N102 requires 233.1416) 234 (base), 216, 154, 
150. 
OH 0 
lt.. II r 
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[ 1-S-( 1a,2a) ]-2-(Hydroxymethyl)-1-( 4-morpholinylcarbonyl)-3,3-
dimethylcyclopropane (86). Prepared by opening lactone 67a with morpholine as 
the amine per the general procedure above. The crude residue was purified by flash 
chromatography (EtOAc/hexanes, 8:2) to afford compound 86 004 mg) as a 
viscous yellow oil. 58% yield; lH NMR (250 MHz) o 3.90 (dd, J = 6.2, 12.2 Hz, 1 
85 
H, Cl "-H), 3.80 - 3.44 (comp, 10 H, C1'-C4'-H, C1"-H, 0-H), 1.46 (d, J = 8.4 Hz, 
C 1-H), 1.40-1.30 (m, 1 H, C2-H), 1.18 (s, 3 H, C5-H), 1.04 (s, 3 H, C6-H); l3c 
NMR (62.5 MHz) o 169.9, 66.9, 59.4, 46.2, 41.9, 31.2, 30.8, 27.6, 22.6, 16.3; IR 
2995, 2490, 1700, 1620, 1460, 1445 cm-I; MS (CI) mlz 213.1354 (C11H19NI03 
requires 213.1365) 
OH 0 
1"'1 ~ I" " ;-\i __ -NH76J2" 3 4. 
_3 1" 




ethylcyclopropane (102). Prepared by opening lactone 74a with benzylamine as 
the amine per the general procedure above. The crude residue was purified by flash 
chromatography (EtOAc/hexanes 8:2) to afford compound 102 (52 mg) as white 
crystals, m.p. 75 °C, 50% yield; IH NMR (250 MHz, CDC13) o 7.37-7.27 (comp, 5 
H, C2"-C7"-H), 6.32 (br s, 1 H, N-H), 4.44 (m, 2 H, C1 "-H), 3.99 (dd, J = 6.6, 12.0 
Hz, 1 H, C1 "'-H), 3.87 (dd, J = 9.8, 12.0 Hz, 1 H, C1"'-H), 2.96 (br s, 1 H, 0-H), 
1.70-1.43 (comp, 4 H, C2-H, C1-H, C3-H, C1'-H), 1.34-1.20 (m, 1H, C1'-H), 0.95 
(t, J = 7.3Hz, C2'-H); l3C NMR (62.5 MHz, CDCI3) o 171.5, 138.2, 128.7, 127.7, 
127.5, 58.4, 43.2, 25.3, 24.2, 23.4, 17.2, 14.1 cm-I; MS (CI) mlz 233.1494 
(C I4H2oN I 02 requires 233.1494) 
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General procedure for opening lactones with dimethylaluminum amide 
esters of amino acids. A 2.0 M solution of trimethylaluminum in hexanes (6 equiv) 
was slowly added to a suspension of the amino acid (3 equiv) in 1,1,1-
trichloromethane (TCE) (0.24 M). The reaction mixture was stirred at room 
temperature until all of the amino acid dissolved, where upon the cyclopropyl 
lactone (1 equiv) was slowly added in TCE (0.12 M). The reaction was refluxed for 
24 h, cooled to 0 oc, and carefully quenched with 2.5 N HCl (1 volume). The 
reaction mixture was extracted with CHC13 (4 x 1 volume), dried (MgS04), and 
concentrated in vacuo. 
[1-R-(la,2a)]-2-(hydroxymethyl)-1-[4-(L-phenylalaninylamino)-
carbonyl]-3-ethylcyclopropane (106). Prepared per general procedure above with 
lactone 74a and amino acid L-phenylalanine. The crude product was purified by 
flash chromatography ( EtOAc/hexanes/ AcOH 88: 1 0:2) to afford compound 106 (51 
mg) as white crystals, m.p. 238 oc, 74% yield; IH NMR (250 MHz) o 7.33-7.18 
87 
(comp, 5 H, C5'-C9'-H}, 7.00 (br s, 1 H, 0-H}, 6.49 (d, J = 7.6 Hz, 1 H, N-H), 4.87 
(m, 1 H, C2'-H), 3.99 (dd, J = 5.3, 12.1 Hz, Cl "'-H), 3.76 (dd, J = 10, 12Hz, C1"'-
H), 3.25 (dd, J = 5.4, 14Hz, C3'-H), 3.07 (dd, J = 6.9, 13.9 Hz, C3'-H), 1.66-1.18 
(comp, 6 H, Cl, C2, C3-H; Cl"-H), 0.90 (t, J = 7.1 Hz, C2"-H); 13C NMR (62.5 
MHz) ~ 174.7, 171.8, 135.9, 129.3, 128.6, 127.,1, 58.3, 53.2, 37.4, 25.6, 24.1~ 23.3, 
20.7, 17.0, 14.0; IR (K.Br) 3375, 2988, 2885, 1740, 1689, 1558; MS (CI) mlz 
291.1471 (C16H2tNt04 requires 291.1470) 292, 274, 243 (base), 154. 
OH 0 O 
l" l____ ~J" 6. 1! OH - - N 2\7 1 3' 6 j3---___ 5 5' 4' 
[1-S-(1a,2a)]-2-(hydroxymethyi)-1-[4-(L-prolinylamino)carbonyl]-3,3-
dimethylcyclopropane (105). Prepared per general procedure above with lactone 
67a and amino acid L-proline. The crude product was purified by flash 
chromatography (EtOAc/ hexanes/AcOH 88:10:2) to afford compound 105 (54 mg) 
as white crystals, m.p. 138-147, 76% yield; lH NMR (250 MHz) ~ 6.5 (br s, 1 H, 
OH), 4.52 (d, J = 5.8, 1 H, C2'-H), 3.98 (dd, J = 6.5, 12.3 Hz, 1 H, Cl "-H), 3.78 (dd 
J = 10.2, 12Hz, 1 H, Cl"-H), 3.59 (t, J = 6.0 Hz, 2 H, C5'-H), 2.39-1.92 (comp, 4 
H, C3', C4'-H), 1.54 (d, J = 8.3 Hz, 1 H, Cl-H) 1.50- 1.27 (comp, 1 H, C2-H) 1.25 
(s, 3 H, C5-H), 1.14 (s, 3 H, C6-H); 13C NMR (62.5 MHz) ~ 173.6, 172.7, 59.5, 
88 
48.1, 32.7, 31.4, 28.3, 28.1, 25.0, 24.7, 15.5; IR (KBr) 3426, 2959, 1734, 1618, 
1464. 
0 0 )_I" !I I' , 
H i {'~Nl2 k I o 4~ 6 --5 3' 
[lS-(la,la)]-1-( 4-morpholinylcarbonyl)·3,3-dimethylcyclopropane-2-
carboxaldehyde (87). PCC (201 mg, 0.94 mmol) and alcohol 86 (100 mg, 0.47 
mmol) were dissolved in dry CH2Cl2 (5 mL). The reaction was stirred for 48 h, 
diluted with Et20 (1 volume}, filtered through celite and glass wool, and 
concentrated in vacuo to afford compound 87 (65 mg) as white crystals, m.p. 950C, 
65% yield; lH NMR (250 MHz) ~ 9.60 {d, J = 6.4 Hz, 1H, C1"-H}, 3.79-3.42 
(comp, 8 H, C1'-C4'-H), 2.19 (d, J = 8.9 Hz, 1 H, C1-H}, 1.79 (dd, J = 6.4, 8.8 Hz, 1 
H, C2-H), 1.44 (s, 3 H, C5-H), m 1.29 (s, 3 H, C6-H); l3C NMR (62.5 MHz) ~ 200, 
166.7, 66.9, 66.8, 46.5, 42.3, 39.3, 39.0, 28.2, 27.4, 16.3 cm-1; IR (CHC13) 3460, 
2842, 2220, 1700, 1642. MS (CI) mlz 212.1294 (C11H18N103 requires 212.1287), 




[1R-( 1 a,2p)]-1-( 4-morpholinylcarbonyl)-3,3-dimethylcyclopropane-2-
carboxaldehyde (88). The cis aldehyde amide 87 (57 mg, 0.27 mmol) was 
dissolved in MeOH (4 mL) which had been purged with nitrogen for 5 min prior to 
use. K2co3 (149 mg, 1.08 mmol) was added to the solution and the reaction was 
stirred at room temperature for 48 h. The reaction was quenched with water (I 
volume), extracted with CH2Cl2 (2 x 15 ml), and concentrated in vacuo to afford 
compound 88 (40 mg, 0.19 mmol) a clear viscous oil. 70% yield; IH NMR (250 
MHz) o 9.79 (d, J = 2.6 Hz, 1 H, Cl "-1), 3.81-3.49 (comp, 8 H, Cl'-C4'-H), 2.69 
(dd, J = 2.6, 5.4 Hz, 1 H, C2-H), 2.50 {d, J = 5.4 Hz, 1 H, Cl-H), 1.29 (s, 3 H, C5-
H), 1.22 {s, 3 H, C6-H); l3C NMR (62.5 MHz) o 199.3, 167.2, 66.9, 66.8, 46.0, 
42.3, 39.6, 35.2, 32.7, 21.2, 19.7; IR (CHCI3) 2840, 1710, 1635, 1440, 1230, 1120 
cm-1; MS (CI) m/z 211.1212 (CuH17N10 3 requires 211.1208). 
General procedure for the Jones oxidation of aldehyde 88 and amide 
alcohols 86, 100, 102 and 103. To an ice cooled solution of the aldehyde or alcohol 
in acetone (0.04 M) was added 8 N Jones reagent (4 equiv), and the reaction was 
stirred for 3 h. The mixture was diluted with 2.5 N HCl (2 volumes), extracted with 
CH2Cl2 (6 x 2 volumes), dried (MgS04), and concentrated in vacuo. 
0 0 
) 4 II r 
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[1S-(la,.2a)]-2-(4-morpholinylcarbonyl)-3,3-dimethylcyclopropane-
carboxylic acid (112). Prepared via the general procedure above from amide 
alcohol 86. The crude acid was purified by flash chromatography (EtOAc/ AcOH, 
98:2) to afford compound 112 {31 mg) as white crystals, m.p. 152 °C, 74% yield; 
lH NMR (250 MHz) o 3.82-3.50 (comp, 8 H, Cl'-C4'-H), 2.35 {d, J = 5.4 Hz, 1 H, 
C1-H), 2.26 (d, J = 5.4 Hz, 1 H, C2-H), 1.36 (s, 3 H, C5-H), 1.18 (s, 3 H, C6-H); 
13C NMR (62.5 MHz) o 175.9, 167.3, 67.0, 66.9, 46.0, 42.4, 34.9, 31.0, 29.7, 21.2, 
19.7; IR (KBr) 3447, 3043, 1718, 1611, 1429, 1244, 1175, 1116; MS(CI) 228.1228 
(C 11H17N10 4 requires 228.1235) 228 (base), 212,210. 
HO 
[1R-(tcx,2p)]-2-( 4-morpholinylcarbonyl)-3,3-dimethyl-cyclopropane-
carboxylic acid (89). Prepared via the general procedure above from amide 
aldehyde 88. The crude acid was purified by flash chromatography (EtOAc/ AcOH, 
98:2) to afford compound 89 (19 mg) as a clear yellow oil. 64% yield; lH NMR 
(250 MHz) o 3.90-3.50 (comp, 8 H, C1'-C4'-H), 2.10 (d, J = 8.0 Hz, C1-H), 1.83 (d, 
J = 7.9 Hz, C1-H), 1.39 (s, 3 H, C5-H), 1.23 (s, 3 H, C6-H); Be NMR (62.5 MHz) 
o 170.8, 170.7, 66.8, 66.6, 46.7, 42.7, 35.5, 34.9, 32.1, 27.6, 26.7, 16.1; IR (CHCI3) 
2960, 2610, 1937, 1735, 1590, 1500 cm-1; MS (CI) LR 228, 217, 158, 141, 
130(base) (CuHt7Nt03 requires 228). 
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[ 1 R-(1 a,2a)]·2·( 4-benzylaminylcarbonyl)-3,3-dimethylcyclopropane-
carboxylic acid (111). Prepared via the general procedure above from amide alcohol 
100. The crude acid was purified by flash chromatography (EtOAc/AcOH, 98:2) to 
afford compound 111 (11 mg) as white crystals, m.p. 149-156 oc, 52% yield; lH 
NMR (250 MHz) B 7.39-7.28 (comp, 5 H, C3'-C7'-H), 7.05 (br s, I H, NH), 4.52 (d, 
J = 5.1Hz, 2 H. CI'-H), 2.04 (d, J = 7.6 Hz, I H, C1-H), 1.76 (d, J = 7.8 Hz, 1 H, 
C2-H), 1.34 (s, 3 H, CS-H), 1.32 (s, 3 H, C6-H); Be NMR (62.5 MHz) B I72.9, 
171.8, 136.8, I28.8, 127.9, 44.4, 36.6, 34.0, 28.6, 27.7, 15.2; IR 322I, 2905, 1710, 






[IS·( 1 a,2a)]-2-( 4-benzylaminykarbonyl)-3,3-dimethylcyclopropane-
carboxylic acid (113). Prepared via the general procedure above from amide alcohol 
103. The crude acid was purified by flash chromatography (EtOAc/AcOH, 98:2) to 
92 
afford compound 113 (13 mg) as a clear syrup. 59% yield; 1 H NMR, nc NMR, 
IR, and MS spectra were identical to 112 above. 
[1S-(1a,2a)]-2-(4-benzylaminylcarbonyl)-3-ethylcydopropanecarboxylic 
acid (114). Prepared via the general procedure above from amide alcohol 102. The 
crude acid was purified by flash chromatography (EtOAc/AcOH, 98:2) to afford 
compound 114 (15 mg) as white crystals, m.p. 142 OC, 52% yield; lH NMR (250 
MHz) o 7.39-7.29 (comp, 5 H, C3'-C7'-H), 6.96 (br s, 1 H, N-H), 4.60-4.39 (m, 2 H, 
C1'-H), 4.53-4.48 (m, 1 H, Cl-H), 1.97-1.86 (comp, 1 H, C2-H), 1.85-1.69 (comp, 2 
H, Cl"-H, C3-H), 1.42-1.19 (m, 1 H, C1"-H), 0.99' (t, J = 7.2 Hz, C2"-H); Be 
NMR (62.5 MHz) o 173.1, 171.5, 136.7, 128.9, 128.0, 127.9, 44.4, 28.6, 27.5, 25.9, 
16.9, 13.2; IR (CHCl3) 3300, 3000, 1700, 1560, 1460, 1445 cm·l; MS (CI) 
247.1234 (C14H17NI03 requires 247.1208), 247, 243(base), 154, 127. 
General procedure for coupling pepdde mimics with compound 36. The 
cyclopropyl carboxylic acid (2 equiv) and compound 36 (1 equiv) were combined in 
DMF (.015 M). N-methylmorpholine (1.1 equiv) and 1-hydroxybenzotriazole (6 
equiv) were added and the mixture was cooled in a dry ice/carbon tetrachloride bath 
---------------------------------~·---····-·· .. 
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for 5 min before adding N-ethyl-N-(dimethylaminopropyl)carbodimide·HCI (2 
equiv). The bath was allowed to warm to room temperature, and the reaction was 
stirred for 24 h. The solvent was removed in vacuo and the crude reaction products 
were taken up in dry CH2Cl2 (5 volumes). The organic solution was washed with 
saturated aqueous NaHC03 (lx1 volume), dried (MgS04), and concentrated in 
vacuo. mv inhibitor complexes were purified by recrystalization from a mixture of 
CHC13thexanes (1:4). 
MJ-1 (56). Prepared by coupling cyclopropyl carboxylic acid 89 with compound 
36 by the general procedure above. All spectra on partially purified sample 1 H 
NMR (500 MHz) a 7.27- 7.10 (comp, 15 H, C5-9, C5'-9-H), 6.52 (d, J = 8.6 Hz, 2 
H, N-H), 4.23 (m, 2 H, C2, C2'-H), 3.76- 3.47 (comp, 24 H, C17-C20, C17'-C20', 
C1, C1', C3, C3'-H), 2.13 (d, J = 5.2 Hz, 4 H, C11, C11'-H), 2.00 (d, J = 5.2 Hz, 2 
H, C15, C15'-H), 1.20 (s, 6 H, C13C13'-H), 1.03 (s, 6 H, C15, C15'-H); 13C NMR a 
170.2, 167.9, 138.2, 129.2, 128.2, 72.8, 67.0, 66.9, 52.5, 46.0, 42.4, 38.3, 32.9, 32.8, 
28.2, 21.1, 19.7, 14.1; MS (CI) 719.4021 (C.wlissN408 requires 719.4019) 719, 
701, 563, 518, 389, 153(base). 
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